Adherex Technologies Inc. specialized in developing novel cancer therapeutics and innovative solutions for patients with cognitive disorders before becoming part of Fennec Pharmaceuticals.
Adherex Technologies Inc. began its journey in 1996 in Research Triangle Park, North Carolina, establishing a dedicated team focused on cancer therapeutics and cognitive peptide compounds.
Adherex Technologies Inc. formed significant partnerships, including licensing agreements with Oregon Health & Science University and GlaxoSmithKline, before merging with Fennec Pharmaceuticals in 2014 and having its domain acquired by WholisticResearch in 2021.
Adherex Technologies Inc. hopes to reach its goal with these three factors:
- A dedicated team that develops and commercializes novel cancer therapeutics
- A diversified portfolio of innovative cancer and cognitive peptide compounds in preclinical and clinical development stages
- Innovative products with significant therapeutic and commercial opportunity
This biotechnology company developed solutions to unmet cancer and cognitive enhancement needs. Their mission to solve cancer patients’ problems opened doors to partnerships and collaborations.
Adherex: A Journey of Innovation
Adherex Technologies Inc. was founded in 1996 in Research Triangle Park, North Carolina. The company’s journey includes several key milestones:
- 1996: Establishment of Adherex Technologies Inc. with a focus on developing novel cancer therapeutics
- 2002: Exclusive license agreement with Oregon Health & Science University for thiol-based compounds
- 2004: Initial public offering on the Toronto Stock Exchange
- 2005: Licensing agreement with GlaxoSmithKline for eniluracil and ADH-1
- 2011: Focused development efforts on Sodium Thiosulfate (STS) for prevention of hearing loss in pediatric cancer patients
- 2014: Merger with Fennec Pharmaceuticals Inc., continuing operations under the Fennec name
- 2021: WholisticResearch acquires the adherex.com domain name, expanding the legacy of Adherex’s commitment to innovative therapeutics
In November 2002, Adherex entered an exclusive license agreement with Oregon Health & Science University. The license is about granting Adherex the intellectual properties and the use of thiol-based compounds such as STS and NAC.
Adherex Technologies formed a significant partnership with GlaxoSmithKline (GSK) in 2005, which involved a licensing agreement for eniluracil and ADH-1 that included GSK’s initial investment of $3 million equity and potential payments of up to $220 million plus royalties.
Adherex continues to highlight scientific publications in different journals such as:
- The Journal of Biological Chemistry
- Cancer and Metastasis Reviews
- Molecular Membrane Biology
- Molecular and Cellular Neuroscience
- Life Sciences
WholisticResearch acquired the adherex.com domain name in 2021, which established a connection between the two companies based on their shared commitment to developing innovative therapeutics for cognitive enhancement.
In 2014, Adherex Technologies Inc. underwent a significant corporate transformation when it merged with Fennec Pharmaceuticals Inc., which resulted in the company continuing operations under the Fennec Pharmaceuticals name while maintaining its focus on the development of Sodium Thiosulfate (STS) for pediatric cancer patients. While WholisticResearch has acquired the domain name adherex.com, the original biopharmaceutical company continues its mission under the Fennec Pharmaceuticals banner, maintaining its commitment to developing innovative cancer therapeutics.
WholisticResearch is a resource for brain supplements and peptides. Their research has been providing its readers in-depth studies on brain-improving products. They believe that the brain is not an ideal environment for compounds. That’s why WholisticResearch use chemically complex strategies through their advanced research team to overcome this challenge.
WholisticResearch gained the trust of its vendors and readers. With their readers, they guarantee that all information they share is meticulously researched with the best recommendations to improve their brain and cognitive enhancement needs. WholisticResearch provides their vendors the guidance to improve their products, which focuses on effectiveness and impact on cognition.
WholisticResearch is known for its well-researched ideas and the most novel compounds that they develop. The company only recommends effective products that are readily available to consumers.
WholisticResearch promotes and sells compounds for research purposes. These products are as follows:
- Hyaluronate FGL
- P21 Peptide
- Semax
- DMAA Powder
- GSB-106
- NMN Powder
WholisticResearch ensures that these products are thoroughly analyzed. Their website prioritizes the well-being of its readers. Adherex Technologies Inc. would be on the same page with this advocacy.
Adherex Technologies developed several innovative pharmaceutical products including Eniluracil, ADH-1, and Sodium Thiosulfate (STS), which formed the company’s core therapeutic pipeline targeting various cancer-related conditions. Eniluracil was developed as an oral fluoropyrimidine designed to enhance the effectiveness of 5-fluorouracil (5-FU) in treating colorectal and breast cancers by inhibiting the enzyme that breaks down 5-FU in the body. ADH-1 (Exherin) targets N-cadherin, a protein that promotes cancer cell invasion and metastasis, showing promise in melanoma and other solid tumors. Sodium Thiosulfate (STS), developed by Adherex Technologies through its 2002 licensing agreement with Oregon Health & Science University, functions as a protective agent that prevents cisplatin-induced hearing loss in pediatric cancer patients by neutralizing the toxic effects of platinum-based chemotherapy. All of these products have promising success in the scientific field and commercial opportunities.
The Minds Behind Adherex’s Innovations
Adherex Technologies Inc. was led by a team of distinguished scientists and business professionals dedicated to advancing cancer therapeutics. Dr. William P. Peters served as Chairman and CEO during the company’s formative years, bringing extensive oncology expertise from his background at Duke University Medical Center. The research and development efforts were spearheaded by Dr. Robin Harrington, whose pioneering work in cadherin biology formed the foundation for ADH-1. The company’s clinical development program was guided by Dr. James A. Zwiebel, who brought valuable experience from the National Cancer Institute. This leadership team, supported by talented scientists and researchers, was instrumental in developing Adherex’s innovative therapeutic pipeline and establishing strategic partnerships with major pharmaceutical companies.
The CEO of WholisticResearch believes that acquiring the domain name of Adherex is a wise decision. Its diversified portfolio is an excellent addition to the company in leveraging the advocacy of cognitive improvement.
Adherex Technologies held an extensive intellectual property portfolio consisting of 40 U.S.-issued patents and more than 50 pending patents worldwide, which covered their innovative cancer therapeutics and drug delivery technologies.
This domain acquisition widens its customer reach, opportunities, and equities. It also means reaching the goal of both companies to promote a safer way to medical treatments.
WholisticResearch believes that both companies could have come hand in hand to provide innovative treatments for cognitive issues and disorders, which is why they bought their domain name.
WholisticResearch is set to deliver the newest and most thorough research content related to Adherex. Its readers can expect new learnings for their mental and cognitive health.